Clinical Features and Risk Factors of Rapidly Progressive Systemic Sclerosis in a Single Center in China: Anti-RNA Polymerase III Antibodies as a Predictor

被引:1
|
作者
Yu, Qiuxia [1 ,2 ]
Zhang, Jin [1 ,2 ]
Fan, Liyi [3 ]
Yu, Tianhang [3 ]
Liu, Bingbing [1 ,2 ]
Ding, Jian [1 ,2 ]
机构
[1] Lihuili Hosp, Ningbo Med Ctr, Dept Rheumatol & Clin Immunol, Ningbo 315040, Zhejiang, Peoples R China
[2] Ningbo Univ, Li Huili Hosp, Dept Rheumatol & Clin Immunol, Ningbo 315040, Zhejiang, Peoples R China
[3] Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China
关键词
rapidly progressive systemic sclerosis; clinical characteristics; predictors; anti-RNA polymerase III antibodies; malignancy; AUTOANTIBODIES; INVOLVEMENT;
D O I
10.24976/Discov.Med.202335175.20
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: Systemic sclerosis (SSc) have been classified in two clinical subsets (diffuse and limited) based on the extend of skin thickening. In this study, we classified a novel subset of SSc defined rapidly progressive systemic sclerosis (RPSSc), which based on the rate of skin thickening progression and the progressive of interstitial lung disease (ILD). We aimed to evaluate RPSSc clinical characteristics and predictive factors in a Chinese single center. Method: Overall, 75 patients diagnosed with SSc, classified into RPSSc (n = 14) and non-rapidly progressive SSc (non-RPSSc, n = 61) were retrospectively included in the study. Clinical characteristics, disease severity and autoantibodies were collected. Logistic regression, least absolute shrinkage, and selection operator (LASSO) regression analysis was used to identify RPSSc predictors. Receiver operating characteristic (ROC) analysis and Delong test was conducted to evaluate and compare different indexes.Results: RPSSc rate was 18.7%. ILD (64.3%), cardiac involvement (42.9%) were the most common organ system involvement of RPSSc, while Raynaud's phenomenon incidence significantly decreased. Disease duration (12 vs 72, months), sex (42.9% vs 11.5%, male %), SSc subset (85.7% vs 27.9%, diffuse cutaneous SSc (dsSSc) %), modified Rodnan total skin score (mRSS) (20.5 vs 6), Raynaud's phenomenon (64.3% vs 98.4%), cardiac involvement (42.9% vs 18%), higher incidence with malignancy (28.6% vs 1.6%) and positive anti-RNA polymerase III antibodies (ARA) (64.3% vs 1.6%) were statistically significant differences among the RPSSc groups and non-RPSSc groups (p < 0.05). Univariate analysis showed that positive ARA, male, dsSSc and malignancy were RPSSc risk factors, while long-disease duration, Raynaud's phenomenon was RPSSc protective factors. ARA was the strongest factor associated to RPSSc (OR 108, 95% CI 11.287-1033.327, p < 0.001). LASSO logistic regression model identified six factors: Disease duration, dsSSc, malignancy, cardiac involvement, positivity of ARA were RPSSc risk factors, Raynaud's phenomenon was RPSSc protective factors.Conclusions: RPSSc is an SSc clinical category which should be accounted for early detection of organ involvement and close follow-up of malignancy. ARA might be used as a predictor for RPSSc and organ involvement.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 24 条
  • [1] Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies
    Motegi, Sei-ichiro
    Toki, Sayaka
    Yamada, Kazuya
    Uchiyama, Akihiko
    Ishikawa, Osamu
    JOURNAL OF DERMATOLOGY, 2015, 42 (02) : 189 - 192
  • [2] Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies
    Airo', Paolo
    Ceribelli, Angela
    Cavazzana, Ilaria
    Taraborelli, Mara
    Zingarelli, Stefania
    Franceschini, Franco
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (07) : 1329 - 1334
  • [3] Rapidly progressive systemic sclerosis associated with breast carcinoma: Report of a case with anti-RNA polymerase III antibody
    Honma, Masaru
    Komatsu, Shigetsuna
    Igawa, Satomi
    Murakami, Masamoto
    Iizuka, Hajime
    JOURNAL OF DERMATOLOGY, 2012, 39 (06) : 574 - 576
  • [4] Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients
    Liu, Chenxi
    Hou, Yong
    Xu, Dong
    Li, Liubing
    Zhang, Yanfang
    Cheng, Linlin
    Yan, Songxin
    Zhang, Fengchun
    Li, Yongzhe
    CLINICAL RHEUMATOLOGY, 2020, 39 (04) : 1191 - 1197
  • [5] Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis
    Wielosz, Ewa
    Dryglewska, Magdalena
    Majdan, Maria
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (06): : 909 - 914
  • [6] Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients
    Chenxi Liu
    Yong Hou
    Dong Xu
    Liubing Li
    Yanfang Zhang
    Linlin Cheng
    Songxin Yan
    Fengchun Zhang
    Yongzhe Li
    Clinical Rheumatology, 2020, 39 : 1191 - 1197
  • [7] Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
    Parker, J. C.
    Burlingame, R. W.
    Webb, T. T.
    Bunn, C. C.
    RHEUMATOLOGY, 2008, 47 (07) : 976 - 979
  • [8] Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen
    Lazzaroni, Maria-Grazia
    Airo, Paolo
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2018, 3 (03) : 214 - 220
  • [9] Diversity and Epitope Spreading of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: A Potential Biomarker for Skin and Lung Involvement
    Kotani, Hirohito
    Matsuda, Kazuki M.
    Yamaguchi, Kei
    Ono, Chihiro
    Kogo, Emi
    Ogawa, Koji
    Kobayashi, Yuki
    Hisamoto, Teruyoshi
    Kawanabe, Ruriko
    Kuzumi, Ai
    Fukasawa, Takemichi
    Yoshizaki-Ogawa, Asako
    Goshima, Naoki
    Sato, Shinichi
    Yoshizaki, Ayumi
    ARTHRITIS & RHEUMATOLOGY, 2025, 77 (01) : 67 - 79
  • [10] Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression
    Cavazzana, Ilaria
    Angela, Ceribelli
    Paolo, Airo'
    Stefania, Zingarelli
    Angela, Tincani
    Franco, Franceschini
    AUTOIMMUNITY REVIEWS, 2009, 8 (07) : 580 - 584